Taysha Gene Therapies Number of Employees 2020-2023 | TSHA

Taysha Gene Therapies number of employees from 2020 to 2023. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
Taysha Gene Therapies Annual Employee Count
2023 52
2022 65
2021 178
2020 38
2019 10
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.481B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $15.673B 5.66
Dr Reddy's Laboratories (RDY) India $12.551B 19.84
Aspen Pharmacare (APNHY) South Africa $5.574B 0.00
BridgeBio Pharma (BBIO) United States $5.208B 0.00
Bausch Health Cos (BHC) Canada $2.868B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.042B 14.20
Supernus Pharmaceuticals (SUPN) United States $1.695B 0.00
Generation Bio (GBIO) United States $0.211B 0.00
Personalis (PSNL) United States $0.078B 0.00
Assembly Biosciences (ASMB) United States $0.072B 0.00
Acasti Pharma (ACST) Canada $0.028B 0.00
Sol-Gel Technologies (SLGL) Israel $0.024B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00